$17.13
0[0.00%]
Last update: 4:00PM Get Real Time Here
Cross Country Healthcare
(NASDAQ:CCRN)Cross Country Healthcare Stock (NASDAQ:CCRN), Analyst Ratings, Price Targets, Predictions
Cross Country Healthcare Inc has a consensus price target of $19.27, established from looking at the 29 latest analyst ratings. The last 3 analyst ratings were released from Barrington Research, Truist Securities, and Benchmark on February 27, 2024, February 22, 2024, and February 22, 2024. With an average price target of $20.33 between Barrington Research, Truist Securities, and Benchmark, there's an implied 16.59% upside for Cross Country Healthcare Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barrington Research
Truist Securities
Benchmark
JMP Securities
UBS
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cross Country Healthcare
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/27/2024 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 37.61% | Barrington Research | Kevin Steinke | $26 → $24 | Maintains | Outperform | Get Alert |
| 02/22/2024 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | -8.26% | Truist Securities | Tobey Sommer | $22 → $16 | Maintains | Hold | Get Alert |
| 02/22/2024 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 20.41% | Benchmark | Bill Sutherland | $24 → $21 | Maintains | Buy | Get Alert |
| 12/06/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | — | JMP Securities | Constantine Davides | — | Initiates | → Market Perform | Get Alert |
| 11/30/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 26.15% | UBS | A.J. Rice | → $22 | Initiates | → Neutral | Get Alert |
| 11/29/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 49.08% | Barrington Research | Kevin Steinke | $29 → $26 | Maintains | Outperform | Get Alert |
| 11/03/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 26.15% | Truist Securities | Tobey Sommer | $25 → $22 | Maintains | Hold | Get Alert |
| 11/03/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 20.41% | Jefferies | Brian Tanquilut | $32 → $21 | Downgrade | Buy → Hold | Get Alert |
| 10/05/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 83.49% | Jefferies | Brian Tanquilut | $40 → $32 | Maintains | Buy | Get Alert |
| 08/14/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 66.28% | Barrington Research | Kevin Steinke | $35 → $29 | Maintains | Outperform | Get Alert |
| 08/08/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 49.08% | Credit Suisse | Jonathan Yong | $27 → $26 | Maintains | Neutral | Get Alert |
| 06/26/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | — | William Blair | Trevor Romeo | — | Initiates | → Outperform | Get Alert |
| 06/01/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 100.69% | Barrington Research | Kevin Steinke | $42 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 54.82% | Credit Suisse | Jonathan Yong | $32 → $27 | Maintains | Neutral | Get Alert |
| 05/02/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 43.35% | Truist Securities | Tobey Sommer | $38 → $25 | Maintains | Hold | Get Alert |
| 03/10/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 72.02% | Loop Capital | Joseph France | → $30 | Initiates | → Buy | Get Alert |
| 02/23/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 129.36% | Benchmark | Bill Sutherland | $45 → $40 | Maintains | Buy | Get Alert |
| 02/23/2023 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 83.49% | Credit Suisse | Jonathan Yon | $31 → $32 | Maintains | Neutral | Get Alert |
| 11/07/2022 | CCRN | Buy Now | Cross Country Healthcare | $17.44 | 158.03% | Barrington Research | Kevin Steinke | $41 → $45 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Cross Country Healthcare (CCRN)?
The latest price target for Cross Country Healthcare (NASDAQ: CCRN) was reported by Barrington Research on February 27, 2024. The analyst firm set a price target for $24.00 expecting CCRN to rise to within 12 months (a possible 40.11% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cross Country Healthcare (CCRN)?
The latest analyst rating for Cross Country Healthcare (NASDAQ: CCRN) was provided by Barrington Research, and Cross Country Healthcare maintained their outperform rating.
When was the last upgrade for Cross Country Healthcare (CCRN)?
The last upgrade for Cross Country Healthcare Inc happened on January 27, 2022 when Jefferies raised their price target to $27. Jefferies previously had a hold for Cross Country Healthcare Inc.
When was the last downgrade for Cross Country Healthcare (CCRN)?
The last downgrade for Cross Country Healthcare Inc happened on November 3, 2023 when Jefferies changed their price target from $32 to $21 for Cross Country Healthcare Inc.
When is the next analyst rating going to be posted or updated for Cross Country Healthcare (CCRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cross Country Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cross Country Healthcare was filed on February 27, 2024 so you should expect the next rating to be made available sometime around February 27, 2025.
Is the Analyst Rating Cross Country Healthcare (CCRN) correct?
While ratings are subjective and will change, the latest Cross Country Healthcare (CCRN) rating was a maintained with a price target of $26.00 to $24.00. The current price Cross Country Healthcare (CCRN) is trading at is $17.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.